Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 11 Dec 2024 – 20 Aug 2026, limited by PGIM India Healthcare Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | PGIM India Healthcare Fund | Nifty 500 |
|---|---|---|
| 11 Dec 2024 | ₹100.00 | ₹100.00 |
| 31 Jan 2025 | ₹95.29 | ₹92.39 |
| 24 Mar 2025 | ₹95.79 | ₹92.21 |
| 14 May 2025 | ₹97.09 | ₹96.32 |
| 05 Jul 2025 | ₹101.40 | ₹100.87 |
| 25 Aug 2025 | ₹102.00 | ₹98.69 |
| 16 Oct 2025 | ₹102.20 | ₹100.88 |
| 06 Dec 2025 | ₹101.90 | ₹102.04 |
| 26 Jan 2026 | ₹94.99 | ₹97.21 |
| 19 Mar 2026 | ₹98.60 | ₹90.87 |
| 09 May 2026 | ₹109.22 | ₹98.96 |
| 30 Jun 2026 | ₹116.43 | ₹98.45 |
| 20 Aug 2026 | ₹125.25 | ₹100.66 |
| Metric | PGIM India · Direct · IDCW NAV ₹12.50 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| +23.52% | +5.11% | |
| — | +13.02% | |
| — | +11.14% | |
| — | +12.26% | |
| +14.26% | +11.82% | |
| +26.91% | — | |
| — | +14.62% | |
| — | +12.95% | |
| — | +13.24% | |
| Risk | ||
| 13.21% | 15.88% | |
| 1.29 | 0.35 | |
| 1.77 | 0.47 | |
| -14.45% | -25.18% | |
| Nifty 500 | — | |
| — | +1.40% | |
| — | 0.98 | |
| — | 101.5% | |
| — | 97.0% | |
| 0.93% | 1.14% | |
| ₹94.43Cr | ₹1,162Cr | |
| Up to 0.50% | — | |
| None | — | |
| ₹1.00K | — | |
| ₹5.00K | — | |
| 24% | 45% | |
| Puneet Pal | — | |
| 11 Dec 2024 | — | |
| 30 | — | |
| 61.4% | — | |
| -0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.